HCV Drug, Setrobuvir, Gets U.S. Patent
US patent for Anadys Pharma covering setrobuvir
PBR Staff Writer
Published 02 June 2011
The US Patent and Trademark Office has granted Patent No 7,939,524 to Anadys Pharmaceuticals’ setrobuvir (ANA598), a Direct-Acting Antiviral (DAA) in development for chronic hepatitis C virus infection (HCV).
The patent recognizes the company’s intellectual property rights to the composition of matter and methods of use for setrobuvir and related compounds.
Setrobuvir, which has received fast track status from the US Food and Drug Administration, is an HCV RNA polymerase inhibitor that belongs to a chemical class referred to as non-nucleosides.
Continue reading this entire article:
Canine Virus Provides Clue to Hepatitis C Origin
Homeopathy for Managing Hepatitis C